CD4 and neoplasm: Conversely, mc12, mc17, mc19 and mc20 were enriched in both neoplastic and ascitic samples compared to PBMC (mc12 p=0.01 for PBMC vs both ascites and tumor, mc17 p<0.001 for PBMC vs tumor, mc19 p=0.02 for PBMC vs ascites and p<0.001 for PBMC vs tumor, mc20 p=0.03 for PBMC vs ascites and p<0.001 for PBMC vs tumor) and consisted of CD4+ or CD8+ effector memory cells (TEM, CD45RA-CD62L-, mc12, mc19 and mc20) or of double-negative lymphocytes (mc17).